Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 11;15(1):35.
doi: 10.1038/s41408-025-01242-8.

Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study

Lambert Busque #  1   2   3 , Marc-Étienne Beaudet #  4   5 , Michaël Harnois  6 , Hanane Moussa  6 , Natasha Szuber  4   5   6 , Luigina Mollica  4   5   6 , Robert Delage  6   7   8 , Harold Olney  5   6   9 , Pierre Laneuville  6   10   11 , Ghislain Cournoyer  6   12 , Inès Chamakhi  5   6   13 , Marc Lalancette  6   7   8 , Danielle Talbot  6   14 , Vincent Ethier  6   15   16 , Pierre Desjardins  6   16   17 , Sarit Assouline  18   19   20
Affiliations

Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study

Lambert Busque et al. Blood Cancer J. .

Abstract

PubMed Disclaimer

Conflict of interest statement

Competing interests: LB, GC, RD, ML, and VE participated in advisory boards for Novartis. LM, M-EB, DT, and IC have nothing to declare. NS is a clinician scientist of the FRQS. Ethical approval: The study protocol was conducted in accordance with the principles of the Declaration of Helsinki (as revised in 2013) and approved by the Institutional Review Board (IRB) of all participating centers. The approbation is renewed every year with CÉR CIUSSS-EIMTL (ethics committee). Informed consent: All patients signed an informed consent.

Figures

Fig. 1
Fig. 1. Event-free survival.
This figure shows the probability of event-free survival according to the TKI used (imatinib = red, dasatinib = blue, nilotinib = green, bosutinib = burgundy). A is 1 L of treatment, B is 2 L of treatment, and C is 3 L.
Fig. 2
Fig. 2. Cumulative incidence of failure in the first line of treatment.
This figure shows the cumulative incidence of failure in 1 L of treatment according to the TKI used (imatinib = green, dasatinib = blue, nilotinib = green). Panel A shows a cumulative incidence of resistance leading to switching in 1 L. Panel B shows the cumulative incidence of intolerance leading to switching in 1 L.
See this image and copyright information in PMC

Comment in

References

    1. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7. - DOI - PubMed
    1. Lipton JH, Brümmendorf TH, Gambacorti-Passerini C, Garcia-Gutiérrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev. 2022;56:100968. - DOI - PubMed
    1. Atallah E, Sweet K. Treatment-free remission: the new goal in CML therapy. Curr Hematol Malig Rep. 2021;16:433–9. - DOI - PMC - PubMed
    1. Held N, Atallah EL. Real-world management of CML: outcomes and treatment patterns. Curr Hematol Malig Rep. 2023;18:167–75. - DOI - PubMed
    1. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9. - DOI - PubMed

LinkOut - more resources